Eli Lilly and Company (NYSE:LLY)‘s stock had its “overweight” rating reaffirmed by research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Friday. They presently have a $105.00 price objective on the stock, up from their prior price objective of $103.00. Piper Jaffray Companies’ target price suggests a potential upside of 26.63% from the stock’s previous close.

LLY has been the topic of a number of other research reports. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and issued a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Berenberg Bank reissued a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $92.00 target price on shares of Eli Lilly and in a research report on Tuesday, May 16th. Finally, BidaskClub raised shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.07.

Eli Lilly and (LLY) traded up 1.69% during midday trading on Friday, reaching $82.92. 3,961,293 shares of the company were exchanged. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The firm’s 50-day moving average is $80.99 and its 200-day moving average is $82.04. The firm has a market cap of $87.48 billion, a P/E ratio of 35.88 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm posted $0.86 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and will post $4.16 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/09/eli-lilly-and-company-lly-earns-overweight-rating-from-piper-jaffray-companies.html.

In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the sale, the insider now owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders sold a total of 826,900 shares of company stock worth $68,610,132 in the last 90 days. 0.20% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after buying an additional 1,610,885 shares in the last quarter. BlackRock Inc. lifted its position in Eli Lilly and by 2.1% during the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after buying an additional 1,323,259 shares in the last quarter. State Street Corp lifted its position in Eli Lilly and by 1.6% during the 1st quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after buying an additional 651,424 shares in the last quarter. Janus Henderson Group PLC lifted its position in Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after buying an additional 9,223,251 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Eli Lilly and by 8.4% during the 1st quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares in the last quarter. Institutional investors own 75.77% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.